2009-07-02
Reuters
Addex seeks partners to help preserve cash
GENEVA, July 2 (Reuters) - Swiss biotech group Addex <ADXN.S> is looking for partners to help develop several of its drugs, aiming to preserve its cash position through current tough refinancing markets, its chief executive told Reuters.
2009-06-24
Romandie News - L'Information en Direct
Addex: Janssen démarre les essais de phase I du produit ADX71149
Plan-les-Ouates (awp) - La société Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMP), partenaire d'Addex Pharmaceuticals SA, a donné le coup d'envoi d'une série d'essais cliniques de phase I sur le produit candidat...
2009-06-10
BioPharmaceutiques
mGluR5 now a target in multiple indications
Swiss firm Addex Pharmaceuticals, which specialises in allosteric modulation of metabotropic glutamate receptors type 5 (mGluR5)...
2009-06-05
Finanz und Wirtschaft
Addex-CFO: Konsolidierungsjahr verläuft nach Plan ? Cash-Burn-Guidance bestätigt
Zürich (awp) - Die Addex Pharmaceuticals SA legt nach einer starken Wachstumsphase bis ins Geschäftsjahr 2008 vor dem Hintergrund der Finanzkrise nun nicht ganz freiwillig ein Jahr der Konsolidierung...
2009-05-27
Romandie News - L'Information en Direct
Addex: ADX10059 efficace pour les patients souffrant de RGO
Genève (awp) - Addex Pharmaceutical SA a obtenu un succès dans une nouvelle étude contre le reflux gastro-oesophagien (RGO). Le produit-candidat ADX10059 normalise la fonction du sphincter dans la partie inférieure de l'oesophage et réduit ainsi les symptômes du RGO, indique la société...
2009-05-14
HealthCentral.com
Glutamate: A New Key To Migraine Treatment?
, Lead Expert Information presented at the 61st Annual Meeting of the American Academy of Neurology (April, 2009) indicates that glutamate receptors may play a role in Migraine...
2009-04-27
Easybourse
Easybourse Interview de Vincent Mutel
«Nous sommes embarqués dans une politique de contrôle des dépenses»
2009-04-17
Agefi
Addex affute son profil managérial pour maximiser ses ventes
L’arrivée de Vincent Lawton (26 ans chez Merck) doit permettre d’accroître la force de frappe commerciale du groupe.
2009-03-23
MedNous
Addex Pharmaceuticals has cash until early 2012
Addex Pharmaceuticals Ltd said that its cash resources are sufficient to cover its operations until early 2012 without the need to raise additional capital.
2008-12-17
Reuters Industries
Addex starts two Phase II trials for lead drug
ZURICH, Dec 17 (Reuters) - Swiss biotech company Addex (ADXN.S: Quote, Profile, Research, Stock Buzz) said on Wednesday it had started a second Phase II trial of its lead drug ADX10059 in patients with gastroesophageal reflux disease (GERD).
2008-12-17
Cash
Addex startet neue Phase IIb-Studien mit ADX10059 zu GERD und Migräne-Prophylaxe
Genf (AWP) - Die Addex Pharmaceuticals SA lanciert für ihr Hauptprodukt ADX10059 weitere Studien der Phase IIb. Die eine untersucht das Produkt an Patienten mit gastro-ösophagealer Refluxkrankheit (GERD), die andere an solchen mit Migräne, wie die Genfer Biotechgesellschaft am Mittwoch...
2008-12-03
EP Vantage
Headline Xenoport GERD data disappoints
The reaction to news that Xenoport’s experimental GERD drug, XP19986, failed to establish efficacy versus placebo in a phase II trial was, considering the mood of the markets at the moment, predictably negative. The stock plunged 35% to a record low of $18.91.
2008-11-25
Chemistry & Industry
Chemistry & Industry: GPCRs Unbound
New technologies to study membrane proteins promise to speed up drug discovery efforts...
2008-11-19
STOCKNEWS.ch
Addex: Implications of todays Novartis newsflow
The stock is seeing continued buying interest today based on several factors:
2008-11-19
AWP
Addex-Aktie nach Novartis-Update zu mGluR5-Inhibitor gefragt
Zürich (AWP) - Die Aktien der Addex Pharmaceuticals SA ziehen am Mittwoch weiter an.
2008-11-14
Genetic Engineering & Biotechnology News
GPCR Market Exhibits Rapid Diversification
Technologic and Scientific Advances Spark Expansion of the Repertoire of GPCR-Targeted Drugs Ken Rubenstein, Ph.D. The differences in targets between launched and developmental compounds addressing GPCRs reflect a sea change in the pharmaceutical research...
2008-11-13
Bloomberg
Brainstorm at Roche Leads to New Valium-Like Drugs (Update2)
By Dermot Doherty Nov. 13 (Bloomberg) -- Vincent Mutel saw so much potential in a new way of tweaking the brain's circuitry that he left a job he'd had for 15 years to bet his future on a start...
2008-11-13
STOCKNEWS.ch
Addex: Outperformer In Times Of Financial Crisis And Recession?
The Addex approach represents a promising way for creating medicines at a time when the pharmaceutical industry is struggling to find new products.
2008-11-12
Reuters UK
Glaxo venture arm lifts Addex stake to 5 percent
(Reuters) - GlaxoSmithKline (GSK.L: Quote, Profile, Research) has increased its stake in Addex Pharmaceuticals (ADXN.S: Quote, Profile, Research) to 5 percent, the Swiss biotech firm said on...
2008-09-13
Finanz Und Wirschaft
«Unternehmenswert wird steigen»
Addex-CEO Vincent Mutel verhandelt über Kooperation mit einem Pharinakonzern
2008-08-29
DOW JONES NEWSWIRES
FOCUS: Big Pharma Casts A Hungry Eye On Switzerland's Addex
Markets clamor for news about a deal with a big pharmaceutical player.
2008-08-13
Agefi
Addex profite des retombées de l’acquisition de Speedel
La société genevoise a bondi de 9,3% à 45,90 francs hier suite à des rumeurs de rachat.
2008-08-12
Bloomberg
Addex Has Record Increase on Acquisition Speculation
Addex Pharmaceuticals Ltd., the Swiss biotechnology company working with Merck & Co., had a record rise in Zurich trading on speculation it is a takeover target.
2008-05-01
PharmaTelevision
Interview with Addex CEO, Vincent Mutel
Dr. Mutel discusses Addex products, strategy and technology
2008-03-03
MedNous
How Addex Pharmaceuticals secured two multi-million dollar deals with Merck
MedNous, a medical business journal, featured the deals with Merck & Co., Inc.
2008-02-27
Addex Pharmaceuticals
BioBusiness Conference (Jan 2008)
Merck & Co., Inc. and Addex jointly presented our two deals
2008-02-24
The New York Times
Daring to Think Differently About Schizophrenia
NORTH WALES, Pa. SCIENTISTS who develop drugs are familiar with disappointment brilliant theories that don’t pan out or promising compounds derailed by unexpected side effects.
2008-01-07
BioCentury
The difference between 4 and 5
In the space of a month, Addex Pharmaceuticals S.A. and Merck & Co. Inc. have done two deals that help benchmark the value of research-stage and preclinical assets.
2008-01-04
Wall Street Journal
Merck and Addex Reach Deal On Developing Schizophrenia Drug
LONDON -- Addex Pharmaceuticals and Merck & Co. reached a deal to develop a drug candidate for schizophrenia, under which the blue-chip drug giant will pay the Swiss firm up to $702 million in cash plus royalties, the companies announced Thursday.
2008-01-04
The In Vivo Blog
Addex Ups Dealmaking Ante
Addex Pharma today took a step up the dealmaking ladder, partnering its pre-IND positive allosteric modulator ADX63365 and back-up compounds with Merck & Co.
2007-12-10
BioCentury
Modifying Parkinson's
Most drugs for Parkinson’s disease target dopamine, which provides short-term, palliative treatment but is accompanied by neurological side effects and eventually loses efficacy as patients develop tolerance.
2007-05-22
BusinessWeek
The Maturing of Europe's Biotechs
Addex Pharmaceutical's successful initial public offering suggests Old World biotechs are set to deliver products with big potential for returns